Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate
Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.
You may also be interested in...
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines.
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.